Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Determination of Related Protease Inhibition from US Patent US20240059691: "ENZYME INHIBITORS"
Assay data:279 Active, 16 Activity ≤ 1 nM, 253 Activity ≤ 1 µM, 299 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Plasmin Serine protease panel
Assay data:1 Tested
SummaryRelated BioAssays by Target
Inhibition of human plasmin at 5 uM using Ac-RM(O2)YR-pNA as substrate relative to control
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human plasmin using Ac-RM(O2)YR-pNA as substrate
Assay data:2 Active, 2 Activity ≤ 1 µM, 3 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human plasmin by fluorescence based analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of human plasmin using H-d-VLK-AM as substrate assessed as inhibition constant by fluorescence plate reader analysis
Inhibition of human plasmin
Inhibition of plasmin (unknown origin)
Assay data:1 Active, 2 Activity ≤ 1 µM, 8 Tested
Enzymatic Activity Assay from US Patent US20230391761: "SUBSTITUTED S-ALANINATE DERIVATIVES"
Assay data:17 Active, 14 Activity ≤ 1 nM, 17 Activity ≤ 1 µM, 17 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Enzymatic Activity Assay from US Patent US11584735: "Solid forms of a plasma kallikrein inhibitor and salts thereof"
SummaryRelated BioAssays by DepositorRelated BioAssays by Target
Activities on Plasmin (PAR4) from US Patent US11541023: "Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases"
Assay data:2 Active, 2 Tested
SummaryCompounds, ActiveRelated BioAssays by DepositorRelated BioAssays by Target
Activities on Plasmin (Boc-QAR-AMC) from US Patent US11541023: "Compounds and compositions for the treatment of neurodegenerative and inflammatory diseases"
Assay data:5 Active, 1 Activity ≤ 1 µM, 6 Tested
Selectivity interaction (Serine protease panel) EUB0000735a PLG
inhibition of native full length human plasmin using H-D-Val-Leu-Lys-pNA as substrate at 5 uM incubated for 30 mins followed by substrate addition by fluorescence based analysis
Inhibition of human plasmin using Mes-DArg-Phe-Arg-AMC as substrate and measured by fluorescence assay
Inhibition of human plasmin assessed as remaining enzyme activity using H-D-CHA -Ala-Arg-AMC.2AcOH as substrate at 10 uM preincubated for 5 to 15 mins followed by substrate addition and measured at 5 min interval for 2 hrs by fluorescence based envision plate reader method relative to control
Assay data:3 Tested
Inhibition of human plasmin preincubated for 5 mins followed by substrate addition by fluorometer analysis
Binding affinity to human plasmin assessed as inhibition constant using H-D-Valyl-L-leucyl-L-lysine p-Nitroaniline as substrate measured upto 120 mins by spectrophotometric analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on